search
Back to results

Lactulose vs. Polyethylene Glycol as Bowel Preparation for Colonoscopy in Adults

Primary Purpose

Lactulose, Polyethylene Glycol, Bowel Preparation

Status
Recruiting
Phase
Not Applicable
Locations
Uruguay
Study Type
Interventional
Intervention
Lactulose
Polyethylene Glycol 3350
Sponsored by
Hospital de Clínicas Dr. Manuel Quintela
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lactulose

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: - Patients over 18 years with no bowel surgical procedures Exclusion Criteria: Patients willingly deciding not to enter into the study Pregnant women Patient with colonic resections and/or ileostomies Inflammatory bowel disease Colonic optimization by prior colonoscopy with poor preparation Suspected intestinal occlusion or perforation, intussusception Patient with melenas Oral iron intake in the past 10 days Emergency colonoscopy Hypersensitivity to any of the components comprised in preparations. Diabetics Chronic kidney disease in dialysis Uncorrected severe dystonias Severe psychiatric illness (schizophrenia) Low IQ to understand bowel preparation Severe constipation (< 1 weekly stool) Chronic diarrhea with high rate (≥ 4 daily evenly loose consistency stools for more than 4 weeks) Unbalanced heart diseases (ischemic cardiopathology, congestive heart failure, unstable angina, arrhythmias and untreatable high blood pressure) Ascites

Sites / Locations

  • Hospital de ClinicasRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Lactulose group

Polyethylene glycol group

Arm Description

Patients participating in the study shall go on with their usual diet prior to colonoscopy. Three days before avoid consuming fruits, vegetables, seeds and cereals. A low residue soft and liquid diet is allowed. The day before the study, the group receiving lactulose shall take 4 tablets of Bisacodyl (5 mg) the day before the study at 6pm. Then, at 8pm a bottle of 250 mL (162.5g lactulose) of lactulose shall be dissolved in 600 mL of water and all contents (850 mL) shall be taken in 2 hours. At 10pm they have to drink 2 liters still water.

Patients participating in the study shall go on with their usual diet prior to colonoscopy. Three days before avoid consuming fruits, vegetables, seeds and cereals. A low residue soft and liquid diet is allowed. The day before the study, the group receiving polyethylene glycol (PEG) should take 4 tablets of Bisacodyl (5 mg) at 4pm. Then, at 6pm, 3 bottles of PEG (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) shall be dissolved in 3 liters of water (1 bottle per liter) and they shall take half the preparation, that is 1 liter and a half in 2 hours. At 10pm they shall take the remaining contents in 2 hours.

Outcomes

Primary Outcome Measures

Compare lactulose vs. Polyethylene Glycol as bowel cleansing preparation for colonoscopy
Compare the level of bowel preparation (by Boston Bowel Preparation Scale) between two groups with lactulose and Polyethylene Glycol. The minimum and maximum value is 0 and 9, respectively. A proper preparation is consider a Boston Bowel Preparation Scale ≥ 2 scores in each colonic segment. Unsuitable preparation a Boston Bowel Preparation Scale < 2 scores in any of the segments. Score 0: is considered a segment of unprepared colon with mucosa that cannot be observed given the presence of solid stool which does not disappear after cleansing. Score 1: part of the colonic mucosa is observed; other areas cannot be suitably assessed given the presence of staining, residual matter and/or opaque liquid. Score 2: little remaining residual matter and small matter fragments which do not prevent correct visualization of colonic mucosa in said segment. Score 3: colonic mucosa which can be entirely observed with no residual matter nor small fragments of matter and opaque liquid.
Establish Boston Bowel Preparation Scale inter and intra-observer variability
Two researchers shall review the endoscopic study videos and they shall complete the Boston Bowel Preparation Scale inter-observer questionnaire. Results obtained by the endoscopist in charge of the study and the observers shall be compared so as to establish inter-observer variability. Researchers shall analyze one month later again all colonoscopies recorded thus establishing Boston Bowel Preparation Scale of each endoscopy. Then results previously established shall be compared so as to establish intra-observer variability. The minimum and maximum value is 0 and 9, respectively. A proper preparation is consider a Boston Bowel Preparation Scale ≥ 2 scores in each colonic segment. Unsuitable preparation a Boston Bowel Preparation Scale < 2 scores in any of the segments.

Secondary Outcome Measures

Assess tolerance between lactulose and Polyethylene Glycol.
To assess tolerance it will be considered: good tolerance those patients with 3 or less symptoms with no major criterion; regular tolerance those patients with 4-5 symptoms, without major criterion and bad tolerance those patients with 6 or more symptoms or 1 or more major criteria.
Assess adherence between lactulose and Polyethylene Glycol.
To assess adherence it shall be assessed if the preparation was completed as well as the will to repeat the same preparation in the future.
Assess side effects between lactulose and Polyethylene Glycol.
To assess side effects of both preparations that will be considered: nausea, vomiting, abdominal pain or bloating, sickness, lipothymia, palpitations, precordial pain, insomnia, anal pain or burning, dry mouth, tinnitus, unpleasant taste.
Establish colonoscopy global adenoma detection rate with lactulose and Polyethylene Glycol.
It correspond to the number of adenomas/adenocarcinomas (histological diagnosis) divided by the total number of colonoscopies performed times 100.
Establish colonoscopy cecal intubation rate in with lactulose and Polyethylene Glycol.
It correspond to the number colonoscopies visualizing ileocecal valve divided by the total number of colonoscopies performed times 100.

Full Information

First Posted
January 18, 2023
Last Updated
August 7, 2023
Sponsor
Hospital de Clínicas Dr. Manuel Quintela
search

1. Study Identification

Unique Protocol Identification Number
NCT05726344
Brief Title
Lactulose vs. Polyethylene Glycol as Bowel Preparation for Colonoscopy in Adults
Official Title
Lactulose vs. Polyethylene Glycol as Bowel Preparation for Colonoscopy in Adults
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 10, 2023 (Actual)
Primary Completion Date
August 25, 2023 (Anticipated)
Study Completion Date
September 23, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hospital de Clínicas Dr. Manuel Quintela

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Colonoscopy is the gold standard in bowel assessment when there is suspicion of colon and rectum pathology. Bowel cleansing is necessary to ensure an optimal visualization of colonic mucosa, allowing this form of detection and removal of polyps. Nowadays international recommendations have multiple bowel preparations. There are differences among them regarding adherence, tolerance and adverse effects. Lactulose (LAC) is widely used in treating constipation. However, there are some randomized clinical assays using LAC as bowel preparation with excellent results according to bowel preparation and tolerance scales. Adherence to bowel preparation significantly affects the result in the endoscopic study. Safety of polyethylene glycol (PEG) formulations has been validated in several studies, it presents little severe side effects and the advantage of its applicability to patients with several comorbidities (heart, liver and kidney without water deprivation). However, its main disadvantage lies in the need to ingest large amounts of liquid (3-4L), generating intolerance thereto in 15%-45% of patients. Bowel cleansing preparation with PEG is widely used in clinical practice. Considering that according to international studies reporting better tolerance and adherence with LAC; it is suggested to compare the level of bowel preparation, tolerance and adherence between two groups with LAC and PEG.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lactulose, Polyethylene Glycol, Bowel Preparation, Colonoscopy, Bisacodyl

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
An analytical, experimental, prospective study, specifically a triple blind randomized clinical assay (endoscopist, researchers and statistician) in which a bowel preparation is compared for colonoscopy with lactulose vs. Polyethylene Glycol.
Masking
Care ProviderInvestigatorOutcomes Assessor
Masking Description
Triple blind (endoscopist, researchers and statistician) randomized clinical assay.
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Lactulose group
Arm Type
Experimental
Arm Description
Patients participating in the study shall go on with their usual diet prior to colonoscopy. Three days before avoid consuming fruits, vegetables, seeds and cereals. A low residue soft and liquid diet is allowed. The day before the study, the group receiving lactulose shall take 4 tablets of Bisacodyl (5 mg) the day before the study at 6pm. Then, at 8pm a bottle of 250 mL (162.5g lactulose) of lactulose shall be dissolved in 600 mL of water and all contents (850 mL) shall be taken in 2 hours. At 10pm they have to drink 2 liters still water.
Arm Title
Polyethylene glycol group
Arm Type
Experimental
Arm Description
Patients participating in the study shall go on with their usual diet prior to colonoscopy. Three days before avoid consuming fruits, vegetables, seeds and cereals. A low residue soft and liquid diet is allowed. The day before the study, the group receiving polyethylene glycol (PEG) should take 4 tablets of Bisacodyl (5 mg) at 4pm. Then, at 6pm, 3 bottles of PEG (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) shall be dissolved in 3 liters of water (1 bottle per liter) and they shall take half the preparation, that is 1 liter and a half in 2 hours. At 10pm they shall take the remaining contents in 2 hours.
Intervention Type
Drug
Intervention Name(s)
Lactulose
Other Intervention Name(s)
Bisacodyl 20 mg, Water 600 mL
Intervention Description
4 tablets of Bisacodyl (5 mg) + 250 mL (162.5g lactulose) of lactulose + 600 mL of water + 2 L of water
Intervention Type
Drug
Intervention Name(s)
Polyethylene Glycol 3350
Other Intervention Name(s)
Bisacodyl 20 mg, Water 3 L
Intervention Description
4 tablets of Bisacodyl (5 mg) + 3 bottles Polyethylene Glycol 3350 (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) + 3 L of water
Primary Outcome Measure Information:
Title
Compare lactulose vs. Polyethylene Glycol as bowel cleansing preparation for colonoscopy
Description
Compare the level of bowel preparation (by Boston Bowel Preparation Scale) between two groups with lactulose and Polyethylene Glycol. The minimum and maximum value is 0 and 9, respectively. A proper preparation is consider a Boston Bowel Preparation Scale ≥ 2 scores in each colonic segment. Unsuitable preparation a Boston Bowel Preparation Scale < 2 scores in any of the segments. Score 0: is considered a segment of unprepared colon with mucosa that cannot be observed given the presence of solid stool which does not disappear after cleansing. Score 1: part of the colonic mucosa is observed; other areas cannot be suitably assessed given the presence of staining, residual matter and/or opaque liquid. Score 2: little remaining residual matter and small matter fragments which do not prevent correct visualization of colonic mucosa in said segment. Score 3: colonic mucosa which can be entirely observed with no residual matter nor small fragments of matter and opaque liquid.
Time Frame
6 months
Title
Establish Boston Bowel Preparation Scale inter and intra-observer variability
Description
Two researchers shall review the endoscopic study videos and they shall complete the Boston Bowel Preparation Scale inter-observer questionnaire. Results obtained by the endoscopist in charge of the study and the observers shall be compared so as to establish inter-observer variability. Researchers shall analyze one month later again all colonoscopies recorded thus establishing Boston Bowel Preparation Scale of each endoscopy. Then results previously established shall be compared so as to establish intra-observer variability. The minimum and maximum value is 0 and 9, respectively. A proper preparation is consider a Boston Bowel Preparation Scale ≥ 2 scores in each colonic segment. Unsuitable preparation a Boston Bowel Preparation Scale < 2 scores in any of the segments.
Time Frame
7 months
Secondary Outcome Measure Information:
Title
Assess tolerance between lactulose and Polyethylene Glycol.
Description
To assess tolerance it will be considered: good tolerance those patients with 3 or less symptoms with no major criterion; regular tolerance those patients with 4-5 symptoms, without major criterion and bad tolerance those patients with 6 or more symptoms or 1 or more major criteria.
Time Frame
6 months
Title
Assess adherence between lactulose and Polyethylene Glycol.
Description
To assess adherence it shall be assessed if the preparation was completed as well as the will to repeat the same preparation in the future.
Time Frame
6 months
Title
Assess side effects between lactulose and Polyethylene Glycol.
Description
To assess side effects of both preparations that will be considered: nausea, vomiting, abdominal pain or bloating, sickness, lipothymia, palpitations, precordial pain, insomnia, anal pain or burning, dry mouth, tinnitus, unpleasant taste.
Time Frame
6 months
Title
Establish colonoscopy global adenoma detection rate with lactulose and Polyethylene Glycol.
Description
It correspond to the number of adenomas/adenocarcinomas (histological diagnosis) divided by the total number of colonoscopies performed times 100.
Time Frame
6 months
Title
Establish colonoscopy cecal intubation rate in with lactulose and Polyethylene Glycol.
Description
It correspond to the number colonoscopies visualizing ileocecal valve divided by the total number of colonoscopies performed times 100.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: - Patients over 18 years with no bowel surgical procedures Exclusion Criteria: Patients willingly deciding not to enter into the study Pregnant women Patient with colonic resections and/or ileostomies Inflammatory bowel disease Colonic optimization by prior colonoscopy with poor preparation Suspected intestinal occlusion or perforation, intussusception Patient with melenas Oral iron intake in the past 10 days Emergency colonoscopy Hypersensitivity to any of the components comprised in preparations. Diabetics Chronic kidney disease in dialysis Uncorrected severe dystonias Severe psychiatric illness (schizophrenia) Low IQ to understand bowel preparation Severe constipation (< 1 weekly stool) Chronic diarrhea with high rate (≥ 4 daily evenly loose consistency stools for more than 4 weeks) Unbalanced heart diseases (ischemic cardiopathology, congestive heart failure, unstable angina, arrhythmias and untreatable high blood pressure) Ascites
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
IGNACIO MORATORIO
Phone
+59897109598
Email
ignaciomoratorio@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
IGNACIO MORATORIO, MD
Organizational Affiliation
HOSPITAL DE CLINICAS
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
MARIA B RUSSO, MD
Organizational Affiliation
HOSPITAL DE CLINICAS
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
FLORENCIA RODRIGUEZ, MD
Organizational Affiliation
HOSPITAL DE CLINICAS
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital de Clinicas
City
Montevideo
Country
Uruguay
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
IGNACIO MORATORIO, MD
Phone
+59897109598
Email
ignaciomoratorio@gmail.com
First Name & Middle Initial & Last Name & Degree
IGNACIO MORATORIO, MD
First Name & Middle Initial & Last Name & Degree
MARIA B RUSSO, MD
First Name & Middle Initial & Last Name & Degree
FLORENCIA RODRIGUEZ, MD
First Name & Middle Initial & Last Name & Degree
ADRIAN CANAVESI, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Study protocol, Statistical Analysis Plan and Informed Consent Form
IPD Sharing Time Frame
ENDED THE TRIAL

Learn more about this trial

Lactulose vs. Polyethylene Glycol as Bowel Preparation for Colonoscopy in Adults

We'll reach out to this number within 24 hrs